Beauty Launchpad
DECEMBER 5, 2024
James Charles, with 20M+ followers, nailed his Daphne Blake Halloween look using Megalook Hair! Bold colors, 100% human hair, breathable caps, easy wear, and affordable prices make Megalook a top choice for influencers and style lovers.
The Dermatology Digest
DECEMBER 5, 2024
Michael Schön, MD, is now a member of Scinai Immunotherapeutics Ltd’s Scientific Advisory Board. Dr. Schön is a distinguished Professor and Director of the Department of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen in Germany. He also serves as Vice Dean and Deputy Director for Research and Teaching and is the former director of the Lower Saxony Institute of Occupational Dermatology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dermatology Times
DECEMBER 5, 2024
Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.
Beauty Launchpad
DECEMBER 5, 2024
Hair Care brand Rahua expert commentary and key insights suggests that consumers are looking for simplified hair and beauty routines that prioritize wellness and cleanliness.
Beautiful With Brains - Skincare
DECEMBER 5, 2024
You know you should NEVER pop a pimple, right? It’s gross. And spreads the infection around. Yuck. But, come on, you’re doing it anyway. Because, it feels SO satisfying. Doesn’t it? And who wants to wait days for pimples to fade away on their own anyway… Well, while I don’t recommend you pop a pimple […] The post How To Pop A Pimple Like A Derm appeared first on Beautiful With Brains.
Beauty Launchpad
DECEMBER 5, 2024
Together, Booksy and Zowie are empowering hair professionals to streamline their day-to-day business operations with ease.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
The Dermatology Digest
DECEMBER 5, 2024
Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13. APG777 demonstrates a 77-day half-life in a 12-month update from the Phase 1 study in healthy volunteers.
Dermatology Times
DECEMBER 5, 2024
Although all observed treatments showed efficacy, the 30 mg dosage of upadacitinib was most successful in relieving itch for atopic dermatitis patients.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how early recognition of hidradenitis suppurativa coupled with timely initiation of biologic therapies can significantly improve treatment outcomes and prevent disease progression.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how managing patient expectations while implementing combination treatment approaches can optimize outcomes in hidradenitis suppurativa, emphasizing the importance of clear communication about treatment goals and timelines.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.
Dermatology Times
DECEMBER 5, 2024
James Song, MD, discusses how recent advances in vitiligo treatment, including Janus kinase inhibitors and targeted immunotherapies, are transforming the therapeutic landscape with more effective options for repigmentation and disease management.
Dermatology Times
DECEMBER 5, 2024
James Song, MD, discusses how Janus kinase (JAK) inhibitors represent a breakthrough in vitiligo treatment by effectively targeting the immune pathways responsible for depigmentation, offering patients a powerful new therapeutic option with promising repigmentation results.
Dermatology Times
DECEMBER 5, 2024
James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how hidradenitis suppurativa significantly impacts patients' quality of life through chronic pain, skin lesions, and social stigma, while remaining frequently misdiagnosed or diagnosed late due to low disease awareness among healthcare providers.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss future innovations in hidradenitis suppurativa (HS) treatment and recommendations for guidelines and support groups.
Dermatology Times
DECEMBER 5, 2024
Panelists discuss how artificial intelligence could revolutionize HS diagnosis through automated image analysis, pattern recognition of clinical presentations, and improved early detection capabilities, potentially reducing diagnostic delays.
Dermatology Times
DECEMBER 5, 2024
Researchers found integrating dermatologists into primary care reduces costs and improves diagnostic precision for skin conditions.
Expert insights. Personalized for you.
90 
Let's personalize your content